Deregulated glucose metabolism fulfills the energetic and biosynthetic requirements for
tumor growth driven by oncogenes. Because inhibition of oncogenic BRAF causes profound …

The BRAF mutant, BRAF V600E , is expressed in nearly half of melanomas, and oral BRAF
inhibitors induce substantial tumor regression in patients with BRAF V600E metastatic …

Despite the success of therapies targeting oncogenes in cancer, clinical outcomes are
limited by residual disease that ultimately results in relapse. This residual disease is often …

An error was made during the preparation of Figure 6B, resulting in more lines on the graph
than the number of samples shown. In addition, the legend for Figure 6 did not indicate that …

Identification of mechanisms underlying sensitivity and response to targeted therapies, such
as the BRAF inhibitor vemurafenib, is critical in order to improve efficacy of these therapies …

Highlights Selective mRNA transport and translation regulates BRAF inhibitor sensitivity in
BRAF V600 melanoma cells. BRAF targeted therapy reprograms metabolism via selective …

Background/Aims: After BRAF, NRAS is the most commonly mutated oncogene in
melanoma. However therapies targeting NRAS remain elusive. Recent investigations have …

The online supplemental data file has been updated to correct this issue, and the statistical
analysis has been revisited to account for the number of comparisons appropriately. …

Introduction: Liver biopsy is the gold standard diagnostic modality used in assessment of
the underlying cause of liver diseases and staging of the degree of fibrosis. It is an invasive …

Despite the success of therapies targeting oncogenes in cancer, clinical outcomes appear
to be limited by a drug adaptation and tolerance phase where initial pathway inhibition …